FKONCO

Dabur Pharma Limited has informed the Exchange that: "The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Ordinary resolution regarding sale of non-oncology formulations division of the Company under Section 293(1)(a) of the Companies Act, 1956".

Dabur Pharma Limited has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the shareholders' consent to the following Ordinary Resolution, proposed to be passed by Postal Ballot: Ordinary Resolution for sale of 'Non Oncology Formulations Division' of the Company under Section 293 (1) (a) of the Companies Act, 1956. The Board of Directors has appointed Mr. T R Ramamurthy, Practicing Company Secretary as the Scrutinizer, for conducting the postal ballot process.

Dabur Pharma Limited has informed the Exchange that "the Share Allotment Committee of the Board of Directors of the Company at their meeting held on 05.02.2007, i.e. today, has allotted 126376 equity Shares of the company pursuant to exercise of vested Employees Stock Option by 50 employees applicants under "ESOP 2004".

Dabur Pharma Limited has informed the Exchange regarding a news release dated January 31, 2007, titled "Dabur Pharma to Divest its Domestic Non-Oncology Formulations Business ". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_PR_02022007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The Board of Directors of Dabur Pharma Limited at its meeting held on 31st January, 2007 decided to sell / dispose off / transfer the "Non Oncology Formulations Divisions" to Alembic Limited for a consideration of Rs. 1,59,00,00,000/- (Rupees One Hundred Fifty Nine Crores Only) plus Net Working Capital as of 1st April, 2007 and other terms and conditions as per the agreement between the parties. This deal is subject to shareholders and other regulatory / statutory approvals as may be required. Pursuant to Section 192A of the Companies Act,

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 23,2007, titled "Dabur Pharma reports Excellent Financial Results for quarter & nine months ended, December 31, 2006". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_23012007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange on January 23, 2007 that the Board of Directors of the Company at its just concluded meeting has, inter alia, taken the following decisions :- (i) To approve appointment of Mr. Ashok Vij as an Additional Directors of the Company. (ii) To approve appointment of Mr. Vardhan Dharkar, Chief Financial Officer as its new Compliance Officer. The Board also reviewed the progress of Company's upcoming Rs. 100 crores formulation manufacturing facility near Baddi (H.P).

Dabur Pharma Limited has informed the Exchange that the Company has acquired the entire oncology (anti-cancer) sales & distribution business from its partner Biosciences Co. Ltd. in Thailand through its wholly owned subsidiary. The copy of press release in this regard dated January 09, 2007, titled "Dabur Pharma Acquires Sales & Distribution Business in Thailand" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dabur_press_090107.zip target=NEW> For

Dabur Pharma Limited has informed the Exchange that "the Company has launched Nanoxel- a novel drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology based chemotherapy agent. A copy of press release in this regard dated January 04, 2007, titled �Dabur Pharma introduces Nanoxel in India" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_PR_0

Dabur Pharma Limited has informed the Exchange that Mr. V. V. Dharkar has joined the Company as Chief Financial Officer w.e.f December 01, 2006. He will sign all the documents, papers & filling etc, as per Stock Exchange requirements till Company Secretary / Compliance Officer is appointed.

Dabur Pharma Limited has informed the Exchange that the Company's Wholly Owned Subsidiary at United Kingdom, Dabur Oncology Plc. has been granted ANDA approval for its Paclitaxel molecule by USA FDA on November 27,2006.

Dabur Pharma Limited has informed the Exchange that the Share Allotment Committee of the Board of Directors of the Company at their meeting held on October 10, 2006 has allotted 168775 equity shares of the Company pursuant to exercise of vested Employees Stock Option by 74 Employees applicants under "ESOP 2004".

Dabur Pharma Limited has informed the Exchange that the Company's Wholly Owned Subsidiary at United Kingdom, Dabur Oncology Plc. has been granted ANDA approval for its Carboplatin molecule by USA FDA on September 29, 2006.

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 25, 2006 taken the following decisions:- (i) To approve the Audited Annexure and Proforma prescribed to be attached with the Cost Audit Report on the Cost Accounting Records of the Company for the financial years ended March 31, 2005 and March 31, 2006. (ii) To approve formation of a Wholly Owned Subsidiary Company in Thailand.

Dabur Pharma Limited has informed the Exchange that the Board at its meeting held on July 26,2006 took note of the progress of Company's upcoming Rs.100 crores formulation manufacturing facility near Baddi (HP).

Dabur Pharma Limited has informed the Exchange that the Compliance Officer of the Company Mr. Pankaj Kapdeo, Company Secretary has resigned from the Company w.e.f. July 19,2006 and the Company is in the process of appointing another Compliance Officer/Company Secretary.

Dabur Pharma Limited has informed the Exchange that the Shareholders of the company at the AGM held on July 14,2006 unanimously approved all the agenda items contained in the Notice convening the said meeting except the resolution at agenda item no.11 of the notice regarding approval under Sections 81 (1A) of the Companies Act, 1956 for issue of securities in any currency up to USD 25 Million. This resolution was dropped as the shareholders felt that the timing, quantum and the pricing of the issue was not in the best interests of the Company.

Dabur Pharma Limited has submitted to the Exchange a copy of the notice of AGM of the members of the Company scheduled to be held on July 14, 2006. A copy of the notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Dabur Pharma Limited has informed the Exchange that the Board of Directors has recommended a dividend of 20% on its equity shares to its shareholders. The BoDs has decided that dividend on equity shares shall be paid on or after July 19, 2006, if approved at the ensuing AGM.

Dabur Pharma Limited has informed the Exchange that the BoDs at its meeting held on May 16, 2006 has : (1) Convened the Annual General Meeting of the Company on July 14, 2006 (2) Fixed the Book closure period for the purpose of ascertaining the names of shareholders entitled to divided and annual closure from July 03, 2006 to July 14, 2006, if approved at the ensuing AGM.

Dabur Pharma Limited has informed the Exchange that the Board of Directors at its meeting held on May 16, 2006, has authorised issue of equity shares / FCDs / PCDs or any other security upto USD 25 Million in equivalent Indian currency to Qualified Institutional Buyers (QIBs) in terms of SEBI Guidelines for Qualified Institutional Placement (QIP).

Dabur Pharma Limited has informed the Exchange that 1) Ratna Commercial Ent. Pvt. Ltd. has sold 2000000 shares aggregating to 1.28% of the total paid up capital of Dabur Pharma Limited on March 31, 2006 & April 03, 2006. The shareholding of Ratna Commercial Ent. Pvt. Ltd. after the said sale is 15116402 shares aggregating to 9.68% of the total paid up capital of Dabur Pharma Limited. 2) Chowdry Associates has sold 209170 shares aggregating to 0.13% of the total paid up capital of Dabur Pharma Limited on March 31, 2006. The shareholding of Chowdry Associates after the said sale is 18082695 shar

Dabur Pharma Limited has informed the Exchange that :- 1) Puran Associates Pvt.Ltd have acquired 2209170 shares aggregating to 1.41% of the total paid up capital of Dabur Pharma Limited on March 31, 2006 & April 03, 2006. The shareholding of Puran Associates Pvt. Ltd. after the said acquisition is 19424377 shares aggregating to 12.44% of the total paid up capital of Dabur Pharma Limtied. The mode of acquisition is through Inter se transfer. 2) Chowdry Associates and Ratna Commercial Ent. Pvt. Ltd. has sold 3148827 shares aggregating to 2.02% of the total paid up capital of Dabur Pharma Limited

Puran Associates Pvt.Ltd., promoter of Dabur Pharma Ltd. along with the PACs has informed the Exchange that Puran Associates Pvt.Ltd along with PACs(as per attached list) have sold 3148827 shares(939657 shares - sold in open market and 2209170 shares - Inter se transfer amongst promoters) and acquired 2209170 shares(2209170 shares - Inter se transfer amongst promoters) of Dabur Pharma Limited resulting in net sale of 939657 shares aggregating to 0.60% of the total paid up capital of Dabur Pharma Limited . The date of acquisition/sale is : Inter se transfer on March 31,2006 and April 03,2006.Th

Dabur Pharma Limited has informed the Exchange that Dr. (Mrs.) Rama Mukherjee has acquired 10,800 shares aggregating to 0.006% of the total share capital of Dabur Pharma Limited on March 03, 2006. The mode of acquisition is through Market Purchase and the shareholding of Dr. (Mrs.) Rama Mukherjee after the said acquisition is 91,185 shares aggregating to 0.058% of the total share capital of Dabur Pharma Limited.

Dabur Pharma Limited has informed the Exchange that Mr. Ajay Kumar Vij, Director has acquired 46406 shares of Dabur Pharma Limited on February 14, 2006. The mode of acquisition is Direct allotment by company under ESOP Scheme 2004 pursuant to exercise of vested options and the shareholding of Mr. Ajay Kumar Vij after the said acquisition is 49006 shares aggregating to 0.031% of the share capital of Dabur Pharma Limited.

Dabur Pharma Limited has informed the Exchange that the Share Allotment Committee of the Board of Directors of the Company at their meeting held on February 14, 2006 has allotted 143986 equity shares of the Company pursuant to exercise of vested Employee Stock Options by 49 Employee applicants under "ESOP 2004".

Dabur Pharma Limited has informed the Exchange that Dr. (Mrs.) Rama Mukherjee, Director of the Company, has acquired 15,000 shares on February 03, 2006. The mode of acquisition is Market Purchase and the shareholding of Dr. (Mrs.) Rama Mukherjee, after the said acquisition is 80,385 shares aggregating to 0.052% of the total share capital of the Dabur Pharma Limited.

Dabur Pharma Limited has informed the Exchange that the Board of Directors at their meeting held on January 27, 2006 has appointed Mr. Irving Kuczynski (Nominee of International Finance Corporation) and Mr. C K Birla as additional Directors on the Board. The Board also took note of the progress of Company's upcoming Rs.100 Crores formulation manufacturing facility near Baddi (HP).

Dabur Pharma Limited has informed the Exchange that the BODs of the Company at its meeting held on October 26, 2005 took note of the progress of Company's upcoming Rs.100 crore formulation manufacturing facility near Baddi (HP).

Dabur Pharma Limited has informed the Exchange that Dr. (Mrs.) Rama Mukherjee, Director of the Company, has acquired shares of Dabur Pharma Ltd. as follows: (1) 2517 shares on September 26, 2005. (2) 12483 shares on September 27, 2005. (3) 2415 shares on September 28, 2005 (4) 3171 shares on September 29, 2005.(5)9414 shares on September 30, 2005.the mode of purchase is Market Purchase and the shareholding of Dr. (Mrs.) Rama Mukherjee, after the said acquisition is 65385 shares aggregating to 0.042% of the total share capital of the Dabur Pharma Limited.

Dabur Pharma Limited has informed the Exchange that the Compensation Committee of Directors, constituted for the purpose of grant of ESOP to the eligible employees and Directors of the Company, has granted 718,820 Options under ESOP 2004 Scheme at their meeting held on September 1, 2005.

Dabur Pharma Limited has informed the Exchange that at the AGM of the Company held on July 26, 2005, the shareholders of the Company unanimously approved all the resolutions mentioned in the Agenda Notice circulated to all the shareholders of the Company including the following: (1) declared a dividend of 10% (Re.0.10 per share) for the FY ended March 31, 2005; (2) approved appointment of Dr. Naresh Trehan as Director of the Company, and (3) approved all the amendments to Articles of Association of the Company, as proposed.

Dabur Pharma Limited has submitted to the Exchange a copy of the proceedings at the EGM of the Company held on May 30, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dabur Pharma Limited has informed the Exchange that International Finance Corporation have acquired 12,14,5000 shares aggregating to 7.788% of the total paid up capital of Dabur Pharma Ltd. on June 13, 2005 .The mode of acquisition is preferential allotment and the shareholding of International Finance Corporation after the said acquisition is 12,14,5000 shares aggregating to 7.788% of the total paid up capital of Dabur Pharma Limited.

International Finance Corporation has informed the Exchange that they have acquired 12,14,5000 shares aggregating to 7.788% of the total paid up capital of Dabur Pharma Ltd on June 13, 2005 .The mode of acquisition is preferential allotment and the shareholding of International Finance Corporation after the said acquisition is 12,14,5000 shares aggregating to 7.788% of the total paid up capital of the company.

Dabur Pharma Limited has informed the Exchange that pursuant to approval of shareholders at their meeting held on May 30, 2005, the Share allotment committee of Directors of the Company at its meeting held on June 13, 2005, has, inter alia, allotted the following equity shares: (1) 1,21,45,000 equity shares of the face and paid up value of Re.1/- each to International Finance Corporation, and; (2) 1,50,000 equity shares of the face and paid up value of Re.1/- each to trustees of Dabur Research Foundation Employees Trust. The above shares have been allotted at Rs.54/- per equity shares. The tot

Dabur Pharma Limited has informed the Exchange that the Board of Directors in its meeting held on May 30, 2005 has recommended a dividend of 10% on equity shares to its shareholders.

Dabur Pharma Limited has informed the Exchange of the outcome of the board meeting held on May 30,2005 as follows:1)Convened the AGM on July 26,2005.2)Fixed the book closure period for the purpose of ascertaining the names of shareholders entitled to dividend and for the purpose of annual closure from July 12,2005 to July 18,2005, both days inclusive.3)Decided that dividend on equity shares shall be paid on or after July 29,2005 if approved at the ensuing AGM.

Dabur Pharma Limited has informed the Exchange of the outcome of the EGM of the company held on May 30,2005:1)The shareholders unanimously approved issue of equity shares on preferential basis to International Finance corporation and to Dabur Research Foundation Employees Trust, and 2)Unanimously approved amendment to capital clause of the memorandum of association of the company.

Dabur Pharma Limited has informed the Exchange that an EGM of the members of the Company will be held on May 30, 2005. The details of the EGM notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 29, 2005 has inter alia, taken the following decisions: 1) To issue and allot on preferential basis upto 1,22,22,220 equity shares of the face value of Re.1/- each at a price of Rs.54/- per equity share (including premium), to International Finance Corporation, USA. 2) To issue and allot on preferential basis upto 1,50,000 equity shares of the face value of Re.1/- each at a price of Rs.54/- per equity share (including premium), to one or more persons acting as Trustees for Dab

Dabur Pharma Limited has informed the Exchange that Dr. P.S.Srinivasan, Whole time Director of the Company, has resigned form the Board of Directors effective April 18, 2005.

Dabur Pharma Limited has informed the Exchange that Dr. (Mrs.) Rama Mukherjee, Director of the Company has acquired 25800 shares of Dabur Pharma Limited on March 24, 2005 .The mode of acquisition is market purchase and the shareholding of Dr. (Mrs.) Rama Mukherjee, after the said acquisition is 35385 shares aggregating to 0.024% of the share capital of Dabur Pharma Ltd..

Dabur Pharma Limited has informed the Exchange that the company has issued a press release dated January 28, 2005 regarding the unaudited financial results of the Company for the quarter ended December 31, 2004 and also that the Company's Bulk Drug Plant at Kalyani, West Bengal, has received USFDA approval for 'Metaxalone' a muscle relaxant. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dabur Pharma Limited has informed the Exchange that Mr.Ajay Kumar Vij, Director of the Company has sold 7000 shares on November 24,2004 and 3000 shares on December 07,2004.The shareholding of Mr.Ajay Kumar Vij after the said sale is 4100 shares aggregating 0.0028% of shares of Dabur Pharma Ltd.

Dabur Pharma Limited has informed the Exchange that Mr.P.D.Narang, Director of the Company has sold 50900 shares during the period December 07,2004 to December 09,2004 and 25,000 shares on December 15,2004 of Dabur Pharma Limited. The shareholding of Mr.P.D.Narang after the said sale is 36244 shares aggregating 0.025% of the total shareholding of the Company.

Dabur Pharma Limited has informed the Exchange that Mr.P.D.Narang, Director of the Company has sold 20000 shares during the period December 24,2004 to December 27,2004 The shareholding of Mr.P.D.Narang after the said sale is 16244 shares aggregating 0.011% of the total shareholding of the Company.

Dabur Pharma Limited has informed the Exchange that Mr.P.D.Narang, Director of the Company has sold 10244 shares during the period December 30,2004 to December 31,2004 The shareholding of Mr.P.D.Narang after the said sale is 6000 shares aggregating 0.004% of the total shareholding of the Company.

Dabur Pharma Limited has informed the Exchange that the Compensation Committee of Directors, constituted for the purpose of grant of ESOP to the eligible employees and Directors of the Company, has granted 703,864 Options under ESOP 2004 Scheme at their meeting held on January 03,2005.